<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82929">
  <stage>Registered</stage>
  <submitdate>24/06/2008</submitdate>
  <approvaldate>20/01/2009</approvaldate>
  <actrnumber>ACTRN12609000043235</actrnumber>
  <trial_identification>
    <studytitle>Can Calcium and Vitamin D reduce diabetes risk in people at high risk?</studytitle>
    <scientifictitle>Impact of vitamin D and calcium supplementation on the metabolic profile of glucose intolerant and vitamin D deficient obese subjects: a double blind, randomised and controlled trial</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Pre-diabetes (impaired fasting glucose or impaired glucose tolerance)</healthcondition>
    <healthcondition>Obesity</healthcondition>
    <healthcondition>Vitamin D deficiency</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The treatment group will receive both calcium carbonate tablets 1200 mg daily and cholecalciferol tablets 2,000 IU daily for 6 months. Cholecalciferol will be increased to 4,000 IU daily after 2 months if the serum 25-hydroxyvitamin D levels are less than 75 nmol/L.</interventions>
    <comparator>The control group will receive 2 pills of calcium placebo (sugar pills) and 2 pills of vitamin D placebo tablets (sugar pills) for the first 2 months. The number of vitamin D placebo tablets will increase to 4 pills per day for the rest of the study (4 months) whereas the patients will continue to take 2 pills per day of calcium placebo tablets.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Determine if calcium and vitamin D reduces insulin resistance assessed by homeostasis model assessment of insulin resistance(HOMA-IR)</outcome>
      <timepoint>Baseline and 6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Determine if calcium and vitamin D improve glucose-stimulated insulin secretion(insulinogenic index and deconvolution analysis of C-peptide after a glucose load)</outcome>
      <timepoint>Baseline and 6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Determine if calcium and vitamin D improve beta-cell function (disposition index)</outcome>
      <timepoint>Baseline and 6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Determine if vitamin D reduces biochemical markers of inflammation associated with increased cardiovascular risk (serum high-sensitive C-reactive protein, fibrinogen, Interleukin-6, Tumor necrosis factor alpha)</outcome>
      <timepoint>Baseline and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Determine if vitamin D reduces gamma-carboxylation of osteocalcin and increases adiponectin by comparing serum adiponectin levels and the decarboxylated form of osteocalcin before and after treatment</outcome>
      <timepoint>Baseline and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Determine if calcium and vitamin D improve blood pressure.</outcome>
      <timepoint>Blood pressure: 0, 2 and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Determine whether vitamin D requirements are influenced by fat mass assessed by dual X-Ray absorptiometry (DXA)</outcome>
      <timepoint>Baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Determine if calcium and vitamin D improve the lipid profile (serum total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides).</outcome>
      <timepoint>Baseline and 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Vitamin D deficiency; overweight or obese as defined by a body-mass index (BMI) between 25-35 kg/m2; impaired fasting glucose or impaired glucose tolerance confirmed with a 75g 2h oral glucose tolerance test (OGTT).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Pregnancy; Breast-feeding; Renal insufficiency; Cirrhosis; Malabsorption; Hypercalcemia; Hypercalciuria; History of nephrolithiasis; Previous non-traumatic fractures; Active or chronic inflammatory disease;Medications known to affect vitamin D, calcium or bone metabolism over the last 3 months; Pharmacological treatment for obesity or medications known to alter glucose metabolism over the last 3 months; Bariatric surgery planned in the next six months or patients who had undergone bariatric surgery in the past; Commenced regular physical activity (more than 3 times/week) in the last 3 months; More than a 5% change in weight in the last 3 months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomization will be performed by a person external to the study. Allocation will involve contacting the holder of the allocation schedule who will be “off-site”.</concealment>
    <sequence>Subjects will be randomly assigned to one of two groups, with stratification according to sex, age (&lt; or &gt;50 years of age) and BMI (&lt; or &gt;30 kg/m2). We will use simple randomisation by using a randomisation table created by a computer software.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>5/01/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>160</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3011</postcode>
    <postcode>3000</postcode>
    <postcode>3001</postcode>
    <postcode>3002</postcode>
    <postcode>3003</postcode>
    <postcode>3010</postcode>
    <postcode>3050</postcode>
    <postcode>3051</postcode>
    <postcode>3052</postcode>
    <postcode>3205</postcode>
    <postcode>3207</postcode>
    <postcode>8001</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Peter Ebeling</primarysponsorname>
    <primarysponsoraddress>Department of Medicine (RMH/WH)
Cnr Eleanor and Marion Streets
Footscray VIC 3011</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Faculty of Medicine, the University of Melbourne (FRC Research Grant)</fundingname>
      <fundingaddress>Level 6, Medical Building, Grattan Street
Parkville VIC 3010</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Diabetes Australia (DART grant)</fundingname>
      <fundingaddress>Office of Diabetes Research
GPO BOX 3156
CANBERRA  ACT  2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Claudia Gagnon</sponsorname>
      <sponsoraddress>Department of Medicine (RMH/WH)
Cnr Eleanor and Marion Streets
Footscray VIC 3011</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Zhong X Lu</othercollaboratorname>
      <othercollaboratoraddress>103 Victoria Pde
Collingwood VIC 3066</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>A/Professor Robin Daly</othercollaboratorname>
      <othercollaboratoraddress>Department of Medicine (RMH/WH)
Cnr Eleanor and Marion Streets
Footscray VIC 3011</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>A/Professor Andre Carpentier</othercollaboratorname>
      <othercollaboratoraddress>3001, 12th Ave North
Fleurimont, Quebec, Canada
J1H 5N4</othercollaboratoraddress>
      <othercollaboratorcountry>Canada</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Type 2 diabetes is Australia's fastest growing chronic disease. Simple strategies to prevent this disease at an early stage (pre-diabetes) in people at high risk are urgently needed. Recently, a lack of calcium and vitamin D has been associated with the development of diabetes. This 6-month study will determine if taking vitamin D and calcium supplements could decrease diabetes risk and cardiovascular risk factors in overweight or obese people with pre-diabetes who lack vitamin D. It will also increase our understanding of the mechanisms through which vitamin D and calcium alter diabetes and cardiovascular disease risk.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Human Research Ethics Committee of Melbourne Health</ethicname>
      <ethicaddress>Research Directorate
PO Royal Melbourne Hospital
Parkville VIC 3050</ethicaddress>
      <ethicapprovaldate>21/05/2008</ethicapprovaldate>
      <hrec>2007.270</hrec>
      <ethicsubmitdate>21/11/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Peter Ebeling</name>
      <address>Department of Medicine (RMH/WH)
Cnr Eleanor and Marion Streets
Footscray VIC 3011</address>
      <phone>+61 3 8345 6429</phone>
      <fax>+61 3 9318 1157</fax>
      <email>peterre@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Claudia Gagnon</name>
      <address>Department of Medicine (RMH/WH)
Cnr Eleanor and Marion Streets
Footscray VIC 3011</address>
      <phone>+61 3 8345 7117</phone>
      <fax>+61 3 9318 1157</fax>
      <email>cgagnon@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Claudia Gagnon</name>
      <address>Department of Medicine (RMH/WH)
Cnr Eleanor and Marion Streets
Footscray VIC 3011</address>
      <phone>+61 3 8345 7117</phone>
      <fax>+61 3 9318 1157</fax>
      <email>cgagnon@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>